John Theurer Cancer Center

part of Hackensack Meridian Health

John Theurer Cancer Center at Hackensack University Medical Center is New Jersey’s largest and most comprehensive cancer program. In less than 25 years, we’ve become one of the most prominent programs nationwide, with more than 1,200 team members collaborating in a highly subspecialized and multidisciplinary environment.

More people in the New Jersey/New York metropolitan area turn to John Theurer Cancer Center for cancer care each year than to any other facility in New Jersey for our:

  • Comprehensive bone marrow and stem cell transplant program
  • Robust clinical trial portfolio
  • Expertise in the management of hematologic malignancies in adults and children
  • Minimally invasive surgery and advanced radiation oncology approaches
  • Value-based care to improve clinical outcomes and reduce cancer-care costs

A Quarter Century of Progress…

More than 6,000 Bone Marrow Transplants
Since our first autologous bone marrow transplant in 1990 and the opening of New Jersey’s only pediatric bone marrow transplant center, our center has grown to become the largest BMT program in the Tri-State area. We perform well over 400 transplants annually (including about 25 pediatric cases) — in addition to our new BMT program, which opened at Georgetown in 2014 in Washington, DC.

  • Our joint adult-pediatric BMT program is FACT-accredited.
  • We have one of the largest allogeneic BMT programs and one of the biggest programs in the country for multiple myeloma, with over 250 transplants a year.
  • Our dedicated pediatric photophoresis program was created to treat acute and chronic graft-versus-host disease.
  • Pediatric patients with sickle cell disease benefit from one of the largest BMT programs in the nation for treating this illness and other noncancerous hematologic disorders.

Leaders in the Management of Myeloma and Other Hematologic Cancers
Our investigators led major studies leading to the FDA approval of lenalidomide, bortezomib, and carfilzomib for multiple myeloma; imatinib and dasatinib for chronic myelogenous leukemia; and bortezomib, lenalidomide and ibrutinib for lymphoma and chronic lymphocytic leukemia, among others.

  • Patients have access to clinical trials for multiple myeloma at all stages of disease, including innovative studies assessing antibody-drug conjugates, bispecific antibodies, and checkpoint inhibitors.
  • We are one of the few sites around the world offering CAR T-cell therapy for multiple myeloma.
  • Our doctors take a conservative approach to treatment for patients with smoldering multiple myeloma, offering clinical trials assessing immune correlates and other predictors of the most opportune time to initiate treatment in these patients.
  • Starting in summer 2017, we will become one of only 30 centers in the United States to assess CAR T-cell therapy for pediatric acute lymphoblastic leukemia.

Integrating the Latest Technology

  • Our center was one of the earliest adopters of robotic surgery for cancer, established in early 2000. We are the only hospital in the state with three Da Vinci Xi systems. Our Multispecialty Center of Excellence for Robotics is one of the three largest robotic surgery programs in the New York Metropolitan area and achieves the highest volume of minimally invasive oncologic procedures in New Jersey.
  • The Department of Radiation Oncology was the first in New Jersey to offer stereotactic radiosurgery for intracranial lesions. We offer curative and palliative regimens for a variety of cancers using intensity-modulated and image-guided radiation therapy (IMRT/IGRT), Gamma Knife stereotactic radiosurgery, brachytherapy, hypofractionation, and stereotactic body radiation therapy.

Comprehensive Care for Solid Tumors
John Theurer Cancer Center has multidisciplinary teams who care for patients with breast, gastrointestinal, gynecologic, head and neck, central nervous system, skin, thoracic, and urologic cancers and sarcoma. During weekly tumor boards, our experts collectively discuss cases in a multidisciplinary approach to customize a treatment plan that meets the needs of each patient.

  • Our thoracic surgeons perform more than 80 percent of thoracic procedures, including lobectomies and esophagectomies, using minimally invasive approaches. Lung cancer outcomes are exceptional, with a post-lobectomy hospital stay half the national average (two versus four days) and a 0 percent mortality rate (2016 and 2017). More than 100 patients with lung cancer each year enroll in Phase I clinical trials of novel treatments for resectable and metastatic disease.
  • Eighty percent of our patients with primary brain tumors participate in clinical trials — an enrollment rate 50 times higher than the national average — including studies assessing novel devices, checkpoint inhibitors, vaccine-based therapies, and novel cytotoxic drugs.
  • Our Breast Oncology Division, both DSC and NAPBC accredited, is the largest breast cancer program in New Jersey, with over 200 dedicated professionals offering minimally invasive oncoplastic breast surgery, the latest chemotherapy regimens and radiation oncology approaches, and a range of clinical trials for all stages of the disease.
  • The experts in our multidisciplinary Gastrointestinal Oncology Division use innovative strategies to care for patients with colorectal, anal, bile duct, gallbladder, liver, pancreatic, small intestine, and gastric cancers. We have the only dedicated high-volume program for GI cancer care in New Jersey. In concert with the Research Division and Phase I Clinical Trials Program, the team provides access for novel therapies (including immuno-oncology approaches) for patients with GI cancers — particularly those with advanced disease.
  • The urologic cancer team focuses on minimizing long-term complications, particularly using robotic-assisted radical prostatectomy. Our team evaluates novel therapies, such as biological agents and checkpoint inhibitors, for patients with genitourinary malignancies.

…and a Commitment to the Next Generation of Cancer Care

Changing the Future of Cancer through Research
John Theurer Cancer Center conducts more than 350 clinical trials — more than any other cancer center in New Jersey. Our physicians and nurses screen every patient for clinical trial eligibility and enroll more than 500 each year in these pivotal research studies. Through our collaborations with industry sponsors — many headquartered in New Jersey — we offer studies of novel agents that are not available elsewhere, including promising targeted therapies and immunotherapies. Patients can receive the latest evidence-based treatments closer to where they live and work.

  • John Theurer Cancer Center is the top enroller of patients in Phase I clinical trials in New Jersey. Our dedicated Phase I Clinical Trials Program enables patients to receive innovative therapies at this earliest stage of development, including investigational drugs that other centers do not have.
  • Through our partnership with the National Cancer Institute’s Immunology branch, Georgetown University, the Parker Institute for Cancer Immunotherapy, and Memorial Sloan Kettering, we are propelling advances in immunotherapy and cellular therapies.
  • In our Jurist Center for Research and through our affiliations with Georgetown’s Lombardi Cancer Center, the Stevens Institute in New Jersey, and Memorial Sloan Kettering, we are dedicated to translational research. We are opening a comprehensive translational science center and a new medical school in collaboration with Seton Hall University, in Nutley, New Jersey, at the former location of Hoffmann-La Roche.
    Embracing Precision Medicine
  • Through our partnership with Memorial Sloan Kettering, we are using precision medicine to tailor the optimal type and sequence of treatment for each patient. Our combined clinical experience and resources — along with our focus on next-generation analytics — will allow us to implement precision medicine at scale and in the real world.

Implementing Value-Based Care with Big Data
COTA (Cancer Outcomes Tracking and Analysis) is an initiative using “big data” to observe patterns of response to therapy in patients with rare diseases. Through precise classification of patients at diagnosis and real-time analytics, we are empowering oncologists with real-world research grade data, enabling alternative payment models, creating national outcomes benchmarks, accelerating drug discovery and approval, and helping patients make informed decisions about their own care. COTA has the power to improve clinical outcomes and reduce cancer-care costs.